Research Papers:

A molecular signature of normal breast epithelial and stromal cells from Li-Fraumeni syndrome mutation carriers

Brittney-Shea Herbert, Rebecca A. Chanoux, Yunlong Liu, Peter H. Baenziger, Chirayu P. Goswami, Jeanette N. McClintick, Howard J. Edenberg, Robert E. Pennington, Steven M. Lipkin and Levy Kopelovich _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2010; 1:405-422. https://doi.org/10.18632/oncotarget.175

Metrics: PDF 3036 views  |   HTML 3740 views  |   ?  


Received: August 11, 2010, Accepted: October 5, 2010, Published: October 6, 2010

Specific changes in gene expression during cancer initiation should enable discovery of biomarkers for risk assessment, early detection and targets for chemoprevention. It has been previously demonstrated that altered mRNA and proteome signatures of morphologically normal cells bearing a single inherited "hit" in a tumor suppressor gene parallel many changes observed in the corresponding sporadic cancer. Here, we report on the global gene expression profile of morphologically normal, cultured primary breast epithelial and stromal cells from Li-Fraumeni syndrome (LFS) TP53 mutation carriers. Our analyses identified multiple changes in gene expression in both morphologically normal breast epithelial and stromal cells associated with TP53 haploinsufficiency, as well as interlocking pathways. Notably, a dysregulated p53 signaling pathway was readily detectable. Pharmacological intervention with the p53 rescue compounds CP-31398 and PRIMA-1 provided further evidence in support of the central role of p53 in affecting these changes in LFS cells and treatment for this cancer. Because loss of signaling mediated by TP53 is associated with the development and survival of many human tumors, identification of gene expression profiles in morphologically normal cells that carry "one-hit" p53 mutations may reveal novel biomarkers, enabling the discovery of potential targets for chemoprevention of sporadic tumors as well.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 175